Glenmark Specialty Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GLENMARK SPECIALTY, and when can generic versions of GLENMARK SPECIALTY drugs launch?
GLENMARK SPECIALTY has one approved drug.
There are fourteen US patents protecting GLENMARK SPECIALTY drugs.
There are eighty patent family members on GLENMARK SPECIALTY drugs in thirty-two countries and twelve supplementary protection certificates in eleven countries.
Summary for Glenmark Specialty
International Patents: | 80 |
US Patents: | 14 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Glenmark Specialty
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | 10,646,500 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | 11,400,101 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Glenmark Specialty Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Brazil | 112015018252 | ⤷ Try a Trial |
France | 21C1057 | ⤷ Try a Trial |
Australia | 2018260934 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Glenmark Specialty Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3043773 | CA 2021 00050 | Denmark | ⤷ Try a Trial | PRODUCT NAME: MOMETASON ELLER ET SALT DERAF OG OLOPATADIN ELLER ET SALT DERAF; NAT. REG. NO/DATE: 63820 20210706; FIRST REG. NO/DATE: AT 140638 20210426 |
3043773 | 122021000085 | Germany | ⤷ Try a Trial | PRODUCT NAME: MOMETASON ODER EIN SALZ DAVON UND OLOPATADIN ODER EIN SALZ DAVON; NAT. REGISTRATION NO/DATE: 2205824.00.00 20211117; FIRST REGISTRATION: OESTERREICH 140638 20210426 |
0548114 | SPC/GB97/064 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.